Viva Biotech Expands Pharmacology Platform to Support Diverse Drug Modalities

Reuters2025-12-29

<a href="https://laohu8.com/S/01873">Viva Biotech</a> Expands Pharmacology Platform to Support Diverse Drug Modalities

Viva Biotech Holdings has expanded its capabilities by strengthening its integrated pharmacology platform, enhancing its Drug Metabolism and Pharmacokinetics (DMPK), pharmacology, and efficacy services. The company has invested in facility expansion and deeper integration of antibody pharmacokinetics with disease-focused studies across multiple therapeutic areas. This comprehensive platform now supports a wide range of drug modalities, offering end-to-end services from structure-based discovery to IND filing and enabling more data-driven decisions in preclinical drug development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VIVA Biotech Holdings published the original content used to generate this news brief via PR Newswire (Ref. ID: CN54144) on December 29, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2595204152?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-29 14:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595204152","market":"fut","top_or_hot":-1,"title":"Viva Biotech Expands Pharmacology Platform to Support Diverse Drug Modalities","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/01873\">Viva Biotech</a> Expands Pharmacology Platform to Support Diverse Drug Modalities\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VBIZF\">Viva Biotech Holdings</a> has expanded its capabilities by strengthening its integrated pharmacology platform, enhancing its Drug Metabolism and Pharmacokinetics (DMPK), pharmacology, and efficacy services. The company has invested in facility expansion and deeper integration of antibody pharmacokinetics with disease-focused studies across multiple therapeutic areas. This comprehensive platform now supports a wide range of drug modalities, offering end-to-end services from structure-based discovery to IND filing and enabling more data-driven decisions in preclinical drug development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VIVA Biotech Holdings published the original content used to generate this news brief via PR Newswire (Ref. ID: CN54144) on December 29, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viva Biotech Expands Pharmacology Platform to Support Diverse Drug Modalities</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViva Biotech Expands Pharmacology Platform to Support Diverse Drug Modalities\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-29 14:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/01873\">Viva Biotech</a> Expands Pharmacology Platform to Support Diverse Drug Modalities\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VBIZF\">Viva Biotech Holdings</a> has expanded its capabilities by strengthening its integrated pharmacology platform, enhancing its Drug Metabolism and Pharmacokinetics (DMPK), pharmacology, and efficacy services. The company has invested in facility expansion and deeper integration of antibody pharmacokinetics with disease-focused studies across multiple therapeutic areas. This comprehensive platform now supports a wide range of drug modalities, offering end-to-end services from structure-based discovery to IND filing and enabling more data-driven decisions in preclinical drug development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VIVA Biotech Holdings published the original content used to generate this news brief via PR Newswire (Ref. ID: CN54144) on December 29, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01873","symbol_name":"维亚生物","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDLbL7Yfz:1","article_id":"2595204152","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595204152","pubTimestamp":1766988848,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Viva Biotech Holdings has expanded its capabilities by strengthening its integrated pharmacology platform, enhancing its Drug Metabolism and Pharmacokinetics , pharmacology, and efficacy services. The company has invested in facility expansion and deeper integration of antibody pharmacokinetics with disease-focused studies across multiple therapeutic areas. This comprehensive platform now supports a wide range of drug modalities, offering end-to-end services from structure-based discovery to IND filing and enabling more data-driven decisions in preclinical drug development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VIVA Biotech Holdings published the original content used to generate this news brief via PR Newswire  on December 29","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01873":"维亚生物","BK1141":"生命科学工具和服务","BK1576":"医药外包概念"},"translate_title":"维亚生物扩展药理学平台以支持多样化的药物模式","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01873":0.9},"content_text":"Viva Biotech Expands Pharmacology Platform to Support Diverse Drug Modalities\n    \n\nViva Biotech Holdings has expanded its capabilities by strengthening its integrated pharmacology platform, enhancing its Drug Metabolism and Pharmacokinetics (DMPK), pharmacology, and efficacy services. The company has invested in facility expansion and deeper integration of antibody pharmacokinetics with disease-focused studies across multiple therapeutic areas. This comprehensive platform now supports a wide range of drug modalities, offering end-to-end services from structure-based discovery to IND filing and enabling more data-driven decisions in preclinical drug development.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VIVA Biotech Holdings published the original content used to generate this news brief via PR Newswire (Ref. ID: CN54144) on December 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595204152","isCrawlerRequest":true}